Recorded €2.3billion profits between April & June
BioNTech, who along with Pfizer, developed the first widely used Covid-19 vaccine, has seen its profits surge in the second quarter of this year.
The German pharmaceutical firm recorded a net profit of over €2.3 billion, between April & June.
In a press release announcing the profits, it is noted that as of 21st July, over one billion doses "of BNT162b2 vaccine were supplied to more than 100 countries or territories worldwide."
The company says profits from the inoculation will help to develop additional drugs against cancer, and other diseases.
We want to make a difference for individuals and humankind. Our strategy remains focused on bringing our broad pipeline of Next-Generation Immunotherapies and #vaccines to people worldwide to address #cancer and a growing list of infectious diseases: https://t.co/CqJHzkeAXa pic.twitter.com/NBE8xvTfUF
— BioNTech SE (@BioNTech_Group) August 9, 2021
Newbridge Concern Worldwide Worker Documents Ongoing Suffering in Sudan
